55. Relapsing polychondritis Clinical trials / Disease details

Clinical trials : 7 / Drugs : 10 - (DrugBank : 9) / Drug target genes : 12 - Drug target pathways : 100

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2019-003964-30-GB (EUCTR)	22/10/2020	31/07/2020	Biologics in refractory vasculitis (BIOVAS): A pragmatic, randomised, double-blind, placebo-controlled, modified-crossover trial of biologic therapy for refractory vasculitis in adults and children.	Biologics in refractory vasculitis (BIOVAS): A pragmatic, randomised, double-blind, placebo-controlled, modified-crossover trial of biologic therapy for refractory primary non-ANCA associated vasculitis in adults and children - Biologics in refractory vasculitis (BIOVAS)	Non-ANCA associated vasculitides: 1.Giant cell arteritis (GCA)2.Takayasu’s arteritis (TA)3.Polyarteritis nodosa (PAN) or cutaneous polyarteritis unrelated to hepatitis B (CPAN)4.Relapsing polychondritis (RP)5.IgA vasculitis (IgAV)6.Cogan’s syndrome7.Non-infective cryoglobulinaemia8.Primary angiitis of central nervous system (PACNS) MedDRA version: 21.1;Level: PT;Classification code 10047115;Term: Vasculitis;System Organ Class: 10047065 - Vascular disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: Infliximab Product Code: N/A INN or Proposed INN: Infliximab Trade Name: Rituximab Product Name: Rituximab INN or Proposed INN: Rituximab Trade Name: Tocilizumab Product Name: Tocilizumab Product Code: N/A INN or Proposed INN: Tocilizumab	Cambridge University Hospitals NHS Foundation Trust	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	140	Phase 2	United Kingdom
2	NCT04077736 (ClinicalTrials.gov)	September 10, 2019	1/9/2019	Low-dose Recombinant Human IL-2 for the Treatment of Relapsing Polychondritis	A Pilot Study of Low Dose IL-2 in the Treatment of Relapsing Polychondritis	Relapsing Polychondritis	Drug: Interleukin-2	Peking University People's Hospital	NULL	Not yet recruiting	18 Years	70 Years	All	10	Phase 2	NULL
3	JPRN-UMIN000006950	2011/12/01	26/12/2011	Effects of additional inhaled tiotropium in relapsing polychondritis with airway involvement		Relapsing polychondritis	To record subjective symptoms, pulmonary function, airway diameter and dimension 3 months before, at baseline and 3 months following tiotropium	St. Marianna University School of Medicine Division of Respiratory and Infectious Diseases, Department of Internal Medicine	NULL	Complete: follow-up complete	Not applicable	Not applicable	Male and Female	20	Not selected	Japan
4	NCT01272856 (ClinicalTrials.gov)	January 2011	6/1/2011	Study on the Safety of Abatacept in Relapsing Polychondritis	An Open-Label, Single-Center, Phase I Study on the Safety of Abatacept in Relapsing Polychondritis	Relapsing Polychondritis	Drug: Abatacept	Benaroya Research Institute	Bristol-Myers Squibb	Completed	18 Years	80 Years	Both	4	Phase 1	United States
5	JPRN-UMIN000003869	2010/07/01	05/07/2010	A clinical study to establish in diagnostic criteria and treatment guideline of relapsing polychondritis.		Relapsing polychondritis	corticosteroid+methotrexate corticosteroid+ciclosporin	St. Marianna University School of Medicine	NULL	Recruiting	20years-old	Not applicable	Male and Female	30	Not selected	Japan
6	NCT01104480 (ClinicalTrials.gov)	May 2010	13/4/2010	Tocilizumab for Relapsing Polychondritis	Efficacy of Tocilizumab in a Patient With Relapsing Polychondritis	Relapsing Polychondritis	Drug: Tocilizumab	McMaster Children's Hospital	NULL	Withdrawn	12 Years	15 Years	Male	0	Phase 2	Canada
7	NCT01041248 (ClinicalTrials.gov)	January 2010	30/12/2009	Single Patient Study to Treat Relapsing Polychondritis With Tocilizumab	Efficacy of Tocilizumab in a Patient With Relapsing Polychondritis	Relapsing Polychondritis	Drug: Tocilizumab	Children's Hospital of Eastern Ontario	NULL	Completed	N/A	N/A	Male	1	N/A	Canada